Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Roberto Badagliacca (Rome, Italy). Risk assessment in pulmonary arterial hypertension: REVEAL vs EUROPEAN scores. ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease

Member's Comments

No comment yet.

Related content which might interest you: Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Childhood pulmonary arterial hypertension: Insights from REVEAL Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Responsiveness of cambridge pulmonary hypertension outcome review (CAMPHOR) scores and utility in pulmonary hypertension (PH) patients Source: Eur Respir J 2007; 30: Suppl. 51, 343s Year: 2007 Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Risk stratification in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018 Year: 2018 CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 56 (4) 1902096; 10.1183/13993003.02096-2019 Year: 2020